Novo Nordisk A/S (NVO) is a Healthcare company in the Drug Manufacturers General industry. It has a market capitalization of $177.74B, a trailing price-to-earnings ratio of 11.0 and a free-cash-flow yield of 2.4%. Over the most recent reported fiscal year, revenue grew 6.4% and free cash flow per share fell 58.2%. Nama's AI scorecard rates it Buy, 6.0 out of 10. On 12-month momentum it ranks in the lagging band of its market.
AI scorecard
Buy · 6.0/10
Positive, at the low end of Buy. As of Nov 7, 2026.
Momentum
Lagging · -17.7% over 12 months ex. last
Second-worst fifth of its market on the past year's move.
Shariah screen
Shariah Compliant
Passes our debt, cash and income screen; not a scholar's ruling.
Off its high
-72.8%
How far the last close sits under the highest price of the past five years.
Market cap
$177.74B
Trailing P/E
11.0
Price / book
5.4
Price / sales
3.6
FCF yield
2.4%
Dividend yield
4.5%
Gross margin
80.7%
Operating margin
43.1%
Net margin
35.4%
Revenue growth (YoY)
+6.4%
Revenue growth (3-yr annual)
+20.4%
EPS growth (YoY)
+1.8%
FCF/share growth (YoY)
-58.2%
Beta
0.4
Exchange
NYSE
Sector
Healthcare
Industry
Drug Manufacturers General
NVO earnings
Next report: Feb 3, 2027 (Q4 2026, EPS estimate $0.64).
Beat the EPS estimate in 3 of 4 recent quarters.
Quarter
Reported
EPS
Estimate
Surprise
Revenue
Q3 2026
Nov 4, 2026
$0.86
$0.69
+25.3%
$11.82B
Q2 2026
Aug 4, 2026
$0.92
$0.74
+24.1%
$11.72B
Q1 2026
May 5, 2026
$0.99
$1.04
-4.7%
$14.45B
Q4 2025
Feb 3, 2026
$0.90
$0.88
+2.4%
$11.81B
NVO analyst price target
Median target $41.87 from 12 analysts, ranging $39.57 – $61.51.
Nama's AI scorecard currently rates Novo Nordisk A/S Buy (6.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is NVO's P/E ratio?
Novo Nordisk A/S trades at a trailing price-to-earnings ratio of 11.0.
When does NVO report earnings?
Novo Nordisk A/S's next scheduled report is on Feb 3, 2027. Analysts expect EPS of $0.64.
What is the NVO price target?
The median analyst price target from 12 analysts is $41.87, with a range of $39.57 – $61.51.
Is NVO Shariah compliant?
Nama's AAOIFI-style screen reads Novo Nordisk A/S as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.